Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-Day infusion is an active well-tolerated regimen

Anti-Cancer Drugs

Volumn 17, Issue 5, 2006, Pages 571-579

  Sewak, Sanjeev ^a,b   Sorich, Joan ^a   O'Leary, James ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Andrew Love Cancer Centre   (Australia)

Author keywords

9 aminocamptothecin; Chemotherapy; Phase I

Indexed keywords

9 AMINOCAMPTOTHECIN; CYCLOPHOSPHAMIDE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; LACTONE; MACROGOL 400; MANNITOL; METHOTREXATE; N,N DIMETHYLACETAMIDE; PACLITAXEL; PLATINUM;

ADULT; ANEMIA; ARTICLE; BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MEGADOSE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFUSION RATE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STEADY STATE; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT DURATION; VOMITING;

EID: 33748149131     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200606000-00012     Document Type: Article

References (35)

1. Wall M, Wani M, Cook C. Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88:3888.
2. Potmesil M, Arbuck S, Takimoto C, Liebes L, Hochster H. Camptothecin and beyond: pre-clinical and clinical studies. Ann N Y Acad Sci 1996: 803:231-247.
3. Jaxel C, Kohn K, Wani M, Wall M, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase 1. Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res 1989; 49:1465-1469.
4. Hsiang Y, Liu L, Wall M, Wani M, Nicholas A, Manikumar G. DNA topoisomerase 1-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989; 49:4385-4389.
5. Liang M, Dahut W, Quin M, Harold N, Arbuck S, Chen A, et al. Preclinical and clinical studies of a new colloidal dispersion formulation of 9-aminocamptothecin [abstract]. Proc Am Assoc Cancer Res 1996; 37:2954A.
6. Takimoto C, Arbuck S. The camptothecins. In: Chabner B, Longo D (editors): Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott-Raven; 1996. pp. 463-484.
7. Potmesil M, Giovanella B. Preclinical development of 20(S)-camptothecin, 9-aminocamptothecin and other analogues. In: Potmesil M, Pinedo H (editors): Camptothecins: new anti-cancer agents. Boca Raton: CRC Press; 1995. pp. 51-57.
8. Potmesil M, Giovanella B, Liu L, Wall M, Silber R, Stehlin J, et al. Preclinical studies of DNA topoisomerase 1-targeted 9-amino and 10,11-methylenedioxy camptothecins. In: Potmesil M, Kohn K (editors): DNA topoisomerases in cancer. New York: Oxford University Press; 1991. pp. 299-311.
9. Potmesil M, Vardeman D, Kozielski A, Mendoza J, Stehlin J, Giovanella B. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 1995; 55:5637-5641.
10. Chen A, Chiang Y, Potmesil M, Wall M, Wani M, Liu L. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991; 51:6039-6044.
11. Eder J, Rubin E, Stone R, Bryant M, Xu G, Supko J. Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci 1996; 803: 247-255.
12. Supko J, Malspeis L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res 1993; 53:3062-3069.
13. Supko J, Plowman J, Dykes D, Zaharko D. Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) anti-tumor activity in mice and its plasma pharmacokinetics [abstract]. Proc Am Assoc Cancer Res 1992; 33:2578A.
14. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995; 1:269-276.
15. Pazdur R, Diaz-Canton E, Ballard WP, Bradof J, Graham S, Arbuck S, et al. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 1997; 15:2905-2909.
16. Saltz L, Kemeny N, Tong W, Harrison J, Berkery R, Kelsen D, et al. 9-aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer 1997; 80:1727-1732.
17. Wilson W, Little R, Pearson D, Jaffe E, Steinberg S, Cheson B, et al. Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. J Clin Oncol 1998; 16:2345-2351.
18. Takimoto C. Clinical studies with 9-aminocamptothecin. Paper presented at: 8th Conference on DNA Topoisomerases in Therapy, Amsterdam; 1997.
19. Hochster H, Plimack E, Runowicz C, Speyer J, Wallach R, Sorich J, et al. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:120-126.
20. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12:553-559.
21. Rowinsky E, Grochow L, Sartorius S, Bowling M, Kaufmann S, Peereboom D, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor Topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996; 14:1224-1235.
22. Miller CB, O'Reilly S, Sartorius S, Burke P, Kaufmann S, Donehower R, et al. A phase I and pharmacologic study of a combination of cyclophosphamide and topotecan in patients with refractory leukemia [abstract]. Proc Am Soc Clin Onc 1997; 16:712A.
23. Tolcher A, O'Shaughnessy J, Weiss R, Zujewski J, Myhand R, Schneider E, et al. Phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res 1997; 3:755-760.
24. WHO. Handbook for reporting results of cancer treatment. Geneva: WHO; 1979.
25. Takimoto C, Klecker R, Dahut W. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994; 655:97-104.
26. Langevin A, Casto D, Thomas P. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 1998; 16:2494-2499.
27. Herben V, van Gijn R, Schellens J, Schot M, Lieverst J, Hillebrand M, et al. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors. J Clin Oncol 1999; 17:1906-1914.
28. Pantazis P, Kozielski AJ, Vardeman DM. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 1993; 5:273-281.
29. Giovanella B, Stehlin J, Hinz H, Vardeman D, Mendoza J, Potmesil M. Studies on time/dose intensity in treatment of human cancer xenografts with camptothecin analogues [abstract]. Proc Am Assoc Cancer Res 1994; 35:2713A.
30. Burris H, Hanauske A, Johnson R, Marshall M, Kuhn J, Hilsenbeck S, et al. Activity of topotecan, a new topoisomerase I inhibitor against human tumor colony forming units in vitro. J Natl Cancer Inst 1992; 84:1816-1820.
31. Houghton P, Chesire P, Myer L, Stewart C, Synold T. Evaluation of 9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 1991; 31:229-239.
32. Gordon A, Fleagle J, Gutherie D, Parkin D, Gore M, Lacave A, et al. Interim analysis of a phase III randomized trial of doxil/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer [abstract]. Proc Am Soc Clin Onc 2000; 19:1508A.
33. ten Bokkel Huinink W, Gore M, Carmicheal J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15:2183-2193.
34. de Jonge M, Punt C, Gelderblom A, Gerderblom H, Loos W, van Beurden V, et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol 1999; 17:2219-2226.
35. Muggia F, Liebes L, Potmesil M, Hamilton A, Hochster H, Hornreich G, et al. Intraperitoneal topoisomerase-I inhibitors: preliminary findings with 9-aminocamptothecin. Ann N Y Acad Sci 2001; 933:178-187.